IDH1変異性肝内胆管がんに対するイボシデニブ:多センター実世界研究からの洞察
Monica Niger1, Margherita Rimini2, Florian Castet3
1Medical Oncology Department, Fondazione IRCCS Instituto Nazionale dei Tumori di Milano, Milan, Italy.
まとめ
イボシデニブは,初期治療後にIDH1変異性胆管がん (CCA) の治療に有望である. この研究では,イボシデニブが進行性CCA患者の全生存率と全生存率を化学療法と比較して改善した.
科学分野:
- 腫瘍学
- ガン治療薬
- ゲノム医学
背景:
- コランジオカルシノーマ (CCA) は,治療の選択肢が限られており,特に進行した段階で予後が悪い.
- ファーストラインの治療法で治療結果が改善されたが,CCAのセカンドラインの治療は依然として重要な臨床的課題である.
- イボシデニブはイソチラート脱水素酵素1 (IDH1) を標的とする阻害剤で,IDH1変異のCCAの可能性を示しているが,実際の証拠は少ない.
研究 の 目的:
- IDH1変異CCAが進行した患者の大群におけるivosidenibの実効性と安全性を評価する.
- この患者集団におけるイボシデニブ治療とセカンドライン化学療法の結果を比較する.
- 転移したIDH1変異性CCAの治療状況におけるイボシデニブの役割に関する貴重なデータを提供するためです.
主な方法:
- IDH1変異性CCAが進行している46人の患者さんを対象とした多センター観察研究です.
- イボシデニブによる無進行生存率 (PFS),全生存率 (OS),疾病制御率 (DCR),および安全性プロフィールの評価
- イボシデニブとFOLFOX/ CAPOX化学療法の間のPFSとOSを比較するために,治療重量の逆確率 (IPTW) を用いた探索分析.
主要な成果:
- イボシデニブのPFSは3. 7ヶ月,OSは11. 5ヶ月で,DCRは50. 0%でした.
- グレード ≥3の有害事象は,患者の8. 7%で観察され,管理可能な安全性プロファイルを示した.
- FOLFOX/ CAPOXと比較して,IPTW調整した分析により,ivosidenibのPFS (6. 9 vs. 2.1ヶ月) とOS (15. 9 vs.
結論:
- イボシデニブは,少なくとも1つの標準治療を経て転移したIDH1変異CCAを有する患者にとって有効な治療法です.
- 研究は,この特定の患者サブグループにおける従来の化学療法と比較して生存結果を改善するイボシデニブの有効性を支持しています.
- CCAのような稀な癌の治療におけるアイボシデニブの標的治療の可能性を現実世界のデータで確認しました.
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Clinical Trials
8.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.1K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267


